These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39099654)

  • 1. Effect of metabolic syndrome on testosterone levels in patients with metastatic prostate cancer: a real-world retrospective study.
    Zhuo T; Yao X; Mei Y; Yang H; Maimaitiyiming A; Huang X; Lei Z; Wang Y; Tao N; An H
    PeerJ; 2024; 12():e17823. PubMed ID: 39099654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome and metastatic prostate cancer correlation study, a real-world study in a prostate cancer clinical research center, Xinjiang, China.
    An H; Ma D; Mei Y; Wang L; Maimaitiyiming A; Zhuo T; Aihaiti R; Bu K; Huang X; Zhang K; Yao M; Ling C; Li W; Tao N
    Front Endocrinol (Lausanne); 2022; 13():1090763. PubMed ID: 36561563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
    Gómez-Gómez E; Carrasco-Valiente J; Campos-Hernández JP; Blanca-Pedregosa AM; Jiménez-Vacas JM; Ruiz-García J; Valero-Rosa J; Luque RM; Requena-Tapia MJ
    J Cell Mol Med; 2019 Feb; 23(2):934-942. PubMed ID: 30450757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
    Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
    Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma.
    Wang J; Abudurexiti M; Shao N; Wei Y; Zhu Y; Ye DW
    Eur Urol Focus; 2020 Jan; 6(1):53-62. PubMed ID: 30217630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer.
    Léon P; Seisen T; Cussenot O; Drouin SJ; Cattarino S; Compérat E; Renard-Penna R; Mozer P; Bitker MO; Rouprêt M
    Urol Oncol; 2015 Sep; 33(9):384.e21-7. PubMed ID: 25595576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
    Sourbeer KN; Howard LE; Andriole GL; Moreira DM; Castro-Santamaria R; Freedland SJ; Vidal AC
    BJU Int; 2015 May; 115(5):736-43. PubMed ID: 24931061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Syndrome is Associated with Prostate Cancer Diagnosed on Biopsy but not the Gleason Score and the Number of Cancer-Positive Cores: A Prospective Controlled Study.
    Bayraktar Z; Şahin C; Yıldırım S; Karaca Y; Sinanoğlu O
    Arch Esp Urol; 2023 Sep; 76(7):504-510. PubMed ID: 37867335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The subgroup analysis of the prognostic value of the intraductal carcinoma of the prostate in patients with metastatic prostate cancer].
    Zhao JG; Nie L; Chen XQ; Chen N; Zeng H
    Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):422-427. PubMed ID: 31142066
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of metabolic syndrome on prostate cancer final pathology.
    Caliskan S; Kaba S; Özsoy E; Keleş MO; Koca O; Akyüz M; Karaman MI
    J Cancer Res Ther; 2019 Mar; 15(Supplement):S47-S50. PubMed ID: 30900620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
    Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
    Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.
    Kim KH; Han KS; Kim KH; Kim DK; Koo KC; Rha KH; Choi YD; Hong SJ
    Urol Oncol; 2015 Sep; 33(9):383.e17-22. PubMed ID: 26004165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
    García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
    Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
    Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
    Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
    Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
    Culp SH; Schellhammer PF; Williams MB
    Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.
    Preisser F; Bandini M; Nazzani S; Mazzone E; Marchioni M; Tian Z; Chun FKH; Saad F; Briganti A; Haese A; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Eur Urol Oncol; 2020 Oct; 3(5):631-639. PubMed ID: 31411975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of metabolic syndrome and prostate cancer.
    Gacci M; Russo GI; De Nunzio C; Sebastianelli A; Salvi M; Vignozzi L; Tubaro A; Morgia G; Serni S
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):146-155. PubMed ID: 28220805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of Gleason scores in metastatic prostate cancer.
    Rusthoven CG; Carlson JA; Waxweiler TV; Yeh N; Raben D; Flaig TW; Kavanagh BD
    Urol Oncol; 2014 Jul; 32(5):707-13. PubMed ID: 24629494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cryoablation combined with androgen deprivation therapy for newly diagnosed metastatic prostate cancer: a propensity score-based study.
    Wang N; Ye Y; Deng M; Zhao D; Jiang L; Chen D; Wu Z; Wang Y; Li Z; Yang Z; Li J; Zhou F; Li Y
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):837-844. PubMed ID: 33664457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.